Natural Compounds with Activity against Ovarian Cancer: In Memory of Michelle Kendall, an Ovarian Cancer Warrior (1973-2021)
A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Natural Products Chemistry".
Deadline for manuscript submissions: closed (1 March 2023) | Viewed by 4508
Special Issue Editor
Interests: cancer; ovarian cancer; medicinal plants; cannabis; phytocannabinoids; phytomolecules; molecular mechanisms
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Ovarian cancer (OC) is the second most common and the most lethal gynecologic malignancy in the Western world. Late-stage ovarian cancer is incurable in the majority of cases. Most women have advanced disease, for which the standard of care remains as surgery and platinum-based cytotoxic chemotherapy. Additional treatments include targeted therapies that target specifically cancer-related processes necessary for tumor growth, division and spread. Nevertheless, in about 80% of cases, on average, disease relapse is expected after 24 months, and ultimately, multi-drug resistance develops, with very few women surviving five years after diagnosis. A large number of plant compounds have anti-cancer activity. Some plants (e.g., Cannabis sativa, Moringa oleifera, Camellia sinensis, Pao pereira, Xylocarpus granatum, Margaritaria discoidea, and Rauwolfia vomitoria) and molecules (e.g., phytocannabinoids, resveratrol, tetrandrine, naringin, and soy protein) were examined for their anti-OC activity in vivo, in vitro, and in clinical trials. This Special Issue aims to present studies that examine these molecules‘ anti-OC properties, chemical structures, mechanisms of action, structure–activity relationships, and their potential as chemotherapeutic drugs.
Prof. Dr. Hinanit Koltai
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- ovarian cancer
- apoptosis
- stem cells
- anti-tumor
- chemotherapy
- medicinal plants
- phytomolecules
- signaling pathway
